163759-50-0

Basic information

• Product Name: 5'-O-[Bis(4-methoxyphenyl)phenylmethyl]-2'-O-(2-methoxyethyl)-5-methyluridine
• Synonyms: 5'-O-[Bis(4-methoxyphenyl)phenylmethyl]-2'-O-(2-methoxyethyl)-5-methyluridine;5'-O-DMTr- 2'-O-(2-Methoxyethyl)-5-Methyl- uridine;5'-O-(4,4'-Dimethoxytrityl)-2'-O-(2-methoxyethyl)-5-methyluridine;1-((2R,3R,4R,5R)-5-((Bis(4-methoxyphenyl)(phenyl)methoxy)methyl)-4-hydroxy-3-(2-methoxyethoxy)tetrahydrofuran-2-yl)-5-methylpyrimidine-2,4(1H,3H)-dione;2'-O-(2-Methoxyethyl)-5'-O-bis(4-methoxypheny)phenylmethy-5-methyluridine, 97%
• CAS NO: 163759-50-0
• Molecular Formula: C₃₄H₃₈N₂O₉
• Molecular Weight: 618.67352
• Mol File: 163759-50-0.mol
• Article Data: 413

Chemical Properties

• Appearance: /
• Density: 1.32
• PKA: 9.55±0.10(Predicted)
• CAS DataBase Reference: 5'-O-[Bis(4-methoxyphenyl)phenylmethyl]-2'-O-(2-methoxyethyl)-5-methyluridine(CAS DataBase Reference)
• NIST Chemistry Reference: 5'-O-[Bis(4-methoxyphenyl)phenylmethyl]-2'-O-(2-methoxyethyl)-5-methyluridine(163759-50-0)
• EPA Substance Registry System: 5'-O-[Bis(4-methoxyphenyl)phenylmethyl]-2'-O-(2-methoxyethyl)-5-methyluridine(163759-50-0)

Safety Data

• Hazardous Substances Data: 163759-50-0(Hazardous Substances Data)

Usage

Uses

5''-O-DMT-2''-O-(2-methoxyethyl)-5-methyluridine is a protected uridine derivative (U829910) and nucleoside used in the preparation of synthetic nucleic acids.

Upstream product

• 98-07-7 Benzotrichlorid 
• 100-66-3 methoxybenzene 
• 40615-35-8 4,4'-dimethoxytrityl alcohol 
• 163759-49-7 2'-O-(2-methoxyethyl)-5-methyluridine 
• 1463-10-1 5-Methyluridine 
• 26879-47-0 1-(β-L-ribofuranosyl)thymine 
• 67-56-1 methanol 
• 40615-36-9 4,4'-dimethoxytrityl chloride 
• 22423-26-3 O-2,2'-cyclo-5-methyluridine 
• 14983-42-7 tris(2-methoxyethyl)borate 
• 854751-16-9 chloro-bis-(2-methoxy-phenyl)-phenyl-methane 
• 730979-83-6 MOE T DMT succinate 
• 163759-46-4 3-Benzyloxymethyl-1-[(2R,3R,4R,5R)-4-(2,4-dichloro-benzyloxy)-5-(2,4-dichloro-benzyloxymethyl)-3-(2-methoxy-ethoxy)-tetrahydro-furan-2-yl]-5-methyl-1H-pyrimidine-2,4-dione 
• 163759-44-2 1-<2'-O-Acetyl-3',5'-bis-O-(2,4-dichlorobenzyl)-β-D-ribofuranosyl>-3-<(benzyloxy)methyl>thymin 

Downstream Products

• 182496-00-0 2'-O-methoxyethyl-5'-O-dimethoxytrityl-5-methylcytidine 
• 730979-83-6 MOE T DMT succinate 
• 182495-98-3 3'-O-acetyl-2'-O-methoxyethyl-5'-O-dimethoxytrityl-5-methyluridine 
• 1345561-85-4 C₃₇H₄₆N₂O₈Si 
• 1345676-10-9 C₅₈H₆₄N₂O₁₀Si 
• 1345564-44-4 C₅₀H₅₆N₂O₉Si 
• 1345564-47-7 C₂₉H₃₆N₂O₇Si 
• 163759-94-2 MOE 5-Me-C Amidite 
• 844504-17-2 2'-O-(2-methoxy)ethyl-3'-O-(t-butyldiphenyl)silylthymidine 

Relevant articles and documents

Copper(II)nitrate catalyzed regioselective protection of primary alcohols with 4,4′-dimethoxytrityl and 2,7-dimethyl-9-phenyl xanthen-9-yl groups in nucleosides and carbohydrates

Regioselective protection of primary hydroxyl group in nucleoside and carbohydrate analogs was accomplished using dimethoxytrityl alcohol (DMTr-OH) or dimethylpixyl alcohol (DMPx-OH) in presence of copper(II)nitrate as a Lewis acid catalyst. Excellent selectivity was observed for the protection of primary hydroxyl group over secondary while glycosidic bond remain unaffected. Utility of this methodology was further exemplified via DMTr- and DMPx-protection of alipahtic acyclic and cyclic diols.

EFFECTS OF APOLIPOPROTEIN B INHIBITION ON GENE EXPRESSION PROFILES IN ANIMALS

Antisense compounds, compositions and methods are provided for modulating the expression of apolipoprotein B. The compositions comprise antisense compounds, particularly antisense oligonucleotides, targeted to nucleic acids encoding apolipoprotein B. Methods of using these compounds for modulation of apolipoprotein B expression and for treatment of diseases associated with expression of apolipoprotein B are provided. Methods are provided for modulating the expression of genes involved in lipid metabolism, useful in the treatment of conditions associated with cardiovascular risk. Antisense oligonucleotides targeted to apolipoprotein B reduce the level of apolipoprotein B mRNA, lower serum cholesterol and shift liver gene expression profiles from those of an obese animal towards those of a lean animal. Further provided are methods for improving the cardiovascular risk of a subject through antisense inhibition of apolipoprotein B. Also provided are methods for employing antisense oligonucleotides targeted to apolipoprotein B to modulate a cellular pathway or metabolic process.

Antisense modulation of PTP1B expression

Compositions and methods are provided for decreasing blood glucose levels in an animal or for preventing or delaying the onset of a rise in blood glucose levels in an animal, comprising administering to said animal an antisense inhibitor of PTP1B expression in combination with at least one glucose-lowering drug. The present invention is also directed to compositions and methods for improving insulin sensitivity in an animal or for preventing or delaying the onset of insulin resistance in an animal. Also provided are compositions and methods for treating or preventing a metabolic condition in an animal. The metabolic condition may be, e.g., diabetes or obesity.